Details
Stereochemistry | ABSOLUTE |
Molecular Formula | C23H37N5O4S2 |
Molecular Weight | 511.701 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 1 / 1 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
CCNCCS(=O)(=O)NC[C@]1(SC(NC(=O)C(C)(C)C)=NN1C(=O)C(C)(C)C)C2=CC=CC=C2
InChI
InChIKey=YVAFBXLHPINSIK-QHCPKHFHSA-N
InChI=1S/C23H37N5O4S2/c1-8-24-14-15-34(31,32)25-16-23(17-12-10-9-11-13-17)28(19(30)22(5,6)7)27-20(33-23)26-18(29)21(2,3)4/h9-13,24-25H,8,14-16H2,1-7H3,(H,26,27,29)/t23-/m0/s1
Molecular Formula | C23H37N5O4S2 |
Molecular Weight | 511.701 |
Charge | 0 |
Count |
|
Stereochemistry | ABSOLUTE |
Additional Stereochemistry | No |
Defined Stereocenters | 1 / 1 |
E/Z Centers | 0 |
Optical Activity | UNSPECIFIED |
Litronesib is a specific, ATP-uncompetitive, allosteric, and potent small-molecule inhibitor of Eg5 with potential antineoplastic activity. Litronesib selectively inhibits the activity of Eg5, which may result in mitotic disruption, apoptosis and consequently cell death in tumor cells that are actively dividing. Histone-H3 phosphorylation of tumor and proliferating skin cells is a promising pharmacodynamic biomarker for in vivo anticancer activity of litronesib. Litronesib had been in phase I clinical trial for the treatment of solid tumors. The most frequent-related adverse events were hematologic such as neutropenia.
Originator
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: P52732 Gene ID: 3832.0 Gene Symbol: KIF11 Target Organism: Homo sapiens (Human) Sources: https://www.ncbi.nlm.nih.gov/pubmed/24752449 |
PubMed
Title | Date | PubMed |
---|---|---|
A phase 1 and dose-finding study of LY2523355 (litronesib), an Eg5 inhibitor, in Japanese patients with advanced solid tumors. | 2014 Jul |
|
Investigation of the mechanism of racemization of litronesib in aqueous solution: unexpected base-catalyzed inversion of a fully substituted carbon chiral center. | 2014 Sep |
|
A Novel Eg5 Inhibitor (LY2523355) Causes Mitotic Arrest and Apoptosis in Cancer Cells and Shows Potent Antitumor Activity in Xenograft Tumor Models. | 2015 Nov |
|
Two Phase 1 dose-escalation studies exploring multiple regimens of litronesib (LY2523355), an Eg5 inhibitor, in patients with advanced cancer. | 2017 Feb |
|
Crystal structure of the Eg5 - K858 complex and implications for structure-based design of thiadiazole-containing inhibitors. | 2018 Aug 5 |
Patents
Sample Use Guides
In Vivo Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/24752449
Days 1, 2, and 3 every 3 weeks at dose level - 5 mg/m²/day
Route of Administration:
Intravenous
Substance Class |
Chemical
Created
by
admin
on
Edited
Fri Dec 15 16:04:56 GMT 2023
by
admin
on
Fri Dec 15 16:04:56 GMT 2023
|
Record UNII |
6611F8KYCV
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Code | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Systematic Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Systematic Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
NCI_THESAURUS |
C67440
Created by
admin on Fri Dec 15 16:04:56 GMT 2023 , Edited by admin on Fri Dec 15 16:04:56 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
910634-41-2
Created by
admin on Fri Dec 15 16:04:56 GMT 2023 , Edited by admin on Fri Dec 15 16:04:56 GMT 2023
|
PRIMARY | |||
|
9159
Created by
admin on Fri Dec 15 16:04:56 GMT 2023 , Edited by admin on Fri Dec 15 16:04:56 GMT 2023
|
PRIMARY | |||
|
6611F8KYCV
Created by
admin on Fri Dec 15 16:04:56 GMT 2023 , Edited by admin on Fri Dec 15 16:04:56 GMT 2023
|
PRIMARY | |||
|
100000126302
Created by
admin on Fri Dec 15 16:04:56 GMT 2023 , Edited by admin on Fri Dec 15 16:04:56 GMT 2023
|
PRIMARY | |||
|
UU-77
Created by
admin on Fri Dec 15 16:04:56 GMT 2023 , Edited by admin on Fri Dec 15 16:04:56 GMT 2023
|
PRIMARY | |||
|
DB11861
Created by
admin on Fri Dec 15 16:04:56 GMT 2023 , Edited by admin on Fri Dec 15 16:04:56 GMT 2023
|
PRIMARY | |||
|
25167017
Created by
admin on Fri Dec 15 16:04:56 GMT 2023 , Edited by admin on Fri Dec 15 16:04:56 GMT 2023
|
PRIMARY | |||
|
SUB33348
Created by
admin on Fri Dec 15 16:04:56 GMT 2023 , Edited by admin on Fri Dec 15 16:04:56 GMT 2023
|
PRIMARY | |||
|
CHEMBL2105661
Created by
admin on Fri Dec 15 16:04:56 GMT 2023 , Edited by admin on Fri Dec 15 16:04:56 GMT 2023
|
PRIMARY | |||
|
C88328
Created by
admin on Fri Dec 15 16:04:56 GMT 2023 , Edited by admin on Fri Dec 15 16:04:56 GMT 2023
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
TARGET -> INHIBITOR |
IC50
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |